120 related articles for article (PubMed ID: 637906)
1. Thymidine rescue of high-dose methotrexate in humans.
Howell SB; Ensminger WD; Krishan A; Frei E
Cancer Res; 1978 Feb; 38(2):325-30. PubMed ID: 637906
[TBL] [Abstract][Full Text] [Related]
2. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
[TBL] [Abstract][Full Text] [Related]
4. Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate.
Howell SB; Krishan A; Frei E
Cancer Res; 1979 Apr; 39(4):1315-20. PubMed ID: 311245
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
Kirkwood JM; Ensminger W; Rosowsky A; Papathanasopoulos N; Frei E
Cancer Res; 1980 Jan; 40(1):107-13. PubMed ID: 7349890
[TBL] [Abstract][Full Text] [Related]
6. Relative biochemical aspects of low and high doses of methotrexate in mice.
Zaharko DS; Fung WP; Yang KH
Cancer Res; 1977 Jun; 37(6):1602-7. PubMed ID: 870175
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study.
Dady PJ; Taylor GA; Muindi JF; Calvert AH; Smith IE; Smyth JF; Harrap KR
Cancer Treat Rep; 1981; 65 Suppl 1():37-43. PubMed ID: 7326664
[TBL] [Abstract][Full Text] [Related]
8. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
Samuels LL; Straw JA
Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
[TBL] [Abstract][Full Text] [Related]
9. Thymidine requirements for the rescue of patients treated with high-dose methotrexate.
Howell SB; Herbst K; Boss GR; Frei E
Cancer Res; 1980 Jun; 40(6):1824-9. PubMed ID: 7371013
[No Abstract] [Full Text] [Related]
10. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.
Pinedo HM; Zaharko DS; Bull J; Chabner BA
Cancer Res; 1977 Feb; 37(2):445-50. PubMed ID: 832268
[TBL] [Abstract][Full Text] [Related]
11. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors.
Glode LM; Pitman SW; Ensminger WD; Rosowsky A; Papathanasopoulos N; Frei E
Cancer Res; 1979 Sep; 39(9):3707-14. PubMed ID: 383286
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
14. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
15. Effect of very high-dose thymidine infusions on leukemia and lymphoma patients.
Blumenreich MS; Woodcock TM; Andreeff M; Hiddemann W; Chou TC; Vale K; O'Hehir M; Clarkson BD; Young CW
Cancer Res; 1984 May; 44(5):2203-7. PubMed ID: 6713407
[TBL] [Abstract][Full Text] [Related]
16. A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue.
Stoller RG; Kaplan HG; Cummings FJ; Calabresi P
Cancer Res; 1979 Mar; 39(3):908-12. PubMed ID: 311683
[No Abstract] [Full Text] [Related]
17. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
18. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
19. Clinical phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion.
Chiuten DF; Wiernik PH; Zaharko DS; Edwards L
Cancer Res; 1980 Mar; 40(3):818-22. PubMed ID: 7471098
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate with thymidine protection or rescue in advanced head and neck cancer: a phase II study.
Schornagel JH; Leyva A; Pinedo HM
Cancer Treat Rep; 1984 Mar; 68(3):543-5. PubMed ID: 6704983
[No Abstract] [Full Text] [Related]
[Next] [New Search]
